Literature DB >> 2129320

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment.

R H Jay1, M W Rampling, D J Betteridge.   

Abstract

Whole blood and plasma viscosity, red cell aggregability and deformability, and plasma fibrinogen have been compared between 20 patients with heterozygous familial hypercholesterolaemia (FH), without clinical arterial disease, and 20 age- and sex-matched controls. Plasma fibrinogen was elevated in FH, associated with increased whole blood viscosity at low shear rate, plasma viscosity and red cell aggregation. At high shear rate blood viscosity was not elevated, and red cell deformability was normal. The effect of 12 weeks double blind treatment with cholestyramine 16-24 g/day, pravastatin 20 mg b.i.d. or placebo on blood rheology was studied in 17 FH patients. Mean plasma cholesterol fell significantly by 24.7% with pravastatin and 21.5% with cholestyramine, the latter also causing a significant 42% rise in triglyceride. Pravastatin, but not cholestyramine, caused a significant fall in plasma viscosity and fibrinogen, but no change was seen in whole blood rheology. This suggests that the rheological abnormalities in FH are at least partly related to the plasma lipid levels and hence reversible with treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129320     DOI: 10.1016/0021-9150(90)90117-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  HMG-CoA reductase inhibitor use in the aged. A review of clinical experience.

Authors:  C J Lintott; R S Scott
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

2.  Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.

Authors:  A Ugur Ural; M Ilker Yilmaz; Ferit Avcu; Atilla Yalcin
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

Review 3.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 4.  Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk.

Authors:  K F Clemmer; A E Binkoski; S M Coval; G Zhao; P M Kris-Etherton
Journal:  Curr Atheroscler Rep       Date:  2001-11       Impact factor: 5.113

5.  Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.

Authors:  Melinda D Wu; Federico Moccetti; Eran Brown; Brian P Davidson; Tamara Atkinson; J Todd Belcik; George Giraud; P Barton Duell; Sergio Fazio; Hagai Tavori; Sotirios Tsimikas; Jonathan R Lindner
Journal:  JACC Cardiovasc Imaging       Date:  2018-06-19

6.  Routine measurement of fibrinogen concentration. Fibrinogen may be just a marker.

Authors:  R J Jay
Journal:  BMJ       Date:  1993-12-11

Review 7.  Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.

Authors:  Robert Krysiak; Boguslaw Okopień; Zbigniew Herman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Behaviour of human erythrocyte aggregation in presence of autologous lipoproteins.

Authors:  C Saldanha; J Loureiro; C Moreira; J Martins E Silva
Journal:  Biochem Res Int       Date:  2011-09-08

Review 9.  Application of a nitric oxide sensor in biomedicine.

Authors:  Carlota Saldanha; José Pedro Lopes de Almeida; Ana Santos Silva-Herdade
Journal:  Biosensors (Basel)       Date:  2014-02-04

10.  Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome.

Authors:  Lae-Young Jung; Sang-Rok Lee; Jin-Mu Jung; Yi-Shik Kim; Sun-Hwa Lee; Kyoung-Suk Rhee; Jei-Keon Chae; Dong-Hwan Lee; Dal-Sik Kim; Won-Ho Kim; Jae-Ki Ko
Journal:  Korean Circ J       Date:  2016-03-21       Impact factor: 3.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.